About

OZ Biosciences expands its transfection solutions portfolio with the launch of Magnetofectamine™ Kit, the winning combination for optimal transfection efficiency.

Marseille, FRANCE, Jan. 30, 2012

OZ Biosciences SAS, specialized in the development of innovative transfection technologies, announces the launch of Magnetofectamine™, a key new product into its comprehensive line of transfection reagents.

Ideal to transfect primary and hard-to-transfect cells, Magnetofectamine™ is the association of Lipofectamine™ 2000 the most renowned transfection reagent from Life Technologies Corporation (Invitrogen™) with the unique Magnetofection™ based reagent CombiMag, from OZ Biosciences™. The alliance of Lipofectamine™ 2000 and CombiMag reagent leads to increased transfection efficiency, minimized toxicity and enhanced gene expression.

"We are pleased to introduce this synergetic association between the leading transfection reagent, Lipofectamine™ 2000, and one of our most popular Magnetofection™ products, CombiMag. This winning combination demonstrates the significant value of our Magnetofection™ technology in the field of transfection" said Olivier Zelphati, CEO of OZ Biosciences.

Magnetofection™ is a simple and highly efficient method to transfect cells in vitro and in vivo. This magnetic assisted transfection is based on the use of magnetic nanoparticles associated to the nucleic acid. In this way, the magnetic force allows a rapid concentration of genetic material onto cells and promotes cellular uptake.

Lipofectamine™ 2000 is the leading transfection reagent on the market for a simple and effective nucleic acid delivery (DNA and siRNA). In the presence of CombiMag reagent, Lipofectamine™ 2000 delivers DNA at higher efficiencies, from +30 to 500%. With Magnetofectamine™, up to 75% transfection efficiencies can be achieved into many primary cells, such as endothelial, chondrocytes, epithelial and human mesenchymal stem cells. Magnetofectamine™ is effective even with low doses of nucleic acids, resulting in minimized cytotoxicity.

About OZ Biosciences:
OZ Biosciences creates, develops and produces innovative transfection reagents and transduction tools for the scientific community and pharmaceutical industry. As an innovative technology-based company, OZ Biosciences continually provides enabling technologies for the delivery of biomolecules. Located in the Luminy Scientific Park, the heart of important biological research activity in Marseille, France, the company has established a strong position in the field of molecular delivery systems.

For more information please visit www.ozbiosciences.com

Contact: Olivier Zelphati - +33(0)4 86 94 85 16 – contact@ozbiosciences.com

SOURCE: OZ Biosciences

Note to editors
Lipofectamine™ and Invitrogen™ are Trademarks owned by Life Technologies Corporation. Lipofectamine™ 2000 is manufactured by Life Technologies Corporation for OZ Biosciences and provided under license from Life Technologies Corporation.